Methods for treating visceral pain associated with interstitial cystitis by administering antagonist antibodies directed against calcitonin gene-related peptide
The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-CGRP antagonist antibody.
1. A method of reducing incidence of or treating visceral pain associated with interstitial cystitis and/or one or more symptoms of visceral pain associated with interstitial cystitis in an individual, comprising administration of a therapeutically effective amount of an anti-CGRP antagonist antibody to the individual,
wherein the anti-CGRP antibody comprises the following complementarity determining regions (CDRs):
(a) CDR H1 as set forth in SEQ ID NO: 3;
(b) CDR H2 as set forth in SEQ ID NO: 4;
(c) CDR H3 as set forth in SEQ ID NO: 5;
(d) CDR L1 as set forth in SEQ ID NO: 6;
(e) CDR L2 as set forth in SEQ ID NO: 7; and
(f) CDR L3 as set forth in SEQ ID NO: 8.
2. The method of claim 1 , wherein the anti-CGRP antibody comprises a VH domain having the amino acid sequence shown in SEQ ID NO: 1.
3. The method of claim 1 , wherein the anti-CGRP antibody comprises a VL domain having the amino acid sequence shown in SEQ ID NO: 2.
4. The method of claim 1 , wherein the anti-CGRP antibody comprises a VH domain having the amino acid sequence shown in SEQ ID NO: 1 and a VL domain having the amino acid sequence shown in SEQ ID NO: 2.
5. The method of claim 1 , wherein the anti-CGRP antibody is produced by the expression vectors with ATCC Accession Nos. PTA-6867 and/or PTA-6866.
6. The method of claim 1 , wherein the anti-CGRP antibody comprises:
the antibody G1 heavy chain full antibody amino acid sequence shown in SEQ ID NO: 11, with or without the C-terminal lysine; and
the antibody G1 light chain full antibody amino acid sequence shown in SEQ ID NO: 12.